With the regimen that is proposed and used at Johns Hopkins in Baltimore including Cy 50 mg/kg/day on days 3 and 4 followed by G-CSF 5 μg/kg/day, the incidences of acute and chronic GVHD were very low, and nonrelapse mortality was found as 17% in the long term. This evidence concerns the gene CSF3 and chronic graft versus host disease.